Mathieu Lajoie

Mathieu Lajoie

Auto-generated profile, based on publicly available information

Mathieu Lajoie

Goodman Cancer Institute, McGill University, Montreal, Quebec, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2022 in Science Immunology
Verified
Journal Article
Closed access
DMDan Moldoveanu
Dan Moldoveanu
LRLeeAnn Ramsay
LeeAnn Ramsay
MLMathieu Lajoie
Mathieu Lajoie
LALuke Anderson-Trocme
Luke Anderson-Trocme
MLMarine Lingrand
Marine Lingrand
IWIan R. Watson
Ian R. Watson
Melanoma is an immunogenic cancer with a high response rate to immune checkpoint inhibitors (ICIs). It harbors a high mutation burden compared with other cancers and, as a result, has abundant tumor-infiltrating lymphocytes (TILs) within its microenvironment. However, understanding the complex interplay between the stroma, tumor cells, and distinct TIL subsets remains a substantial challenge in immune oncology. To properly study this interplay, quantifying spatial relationships of multiple cell types within the tumor microenvironment is crucial. To address this, we used cytometry time-of-flight (CyTOF) imaging mass cytometry (IMC) to simultaneously quantify the expression of 35 protein markers, characterizing the microenvironment of 5 benign nevi and 67 melanomas. We profiled more than 220,000 individual cells to identify melanoma, lymphocyte subsets, macrophage/monocyte, and stromal cell populations, allowing for in-depth spatial quantification of the melanoma microenvironment. We found that within pretreatment melanomas, the abundance of proliferating antigen-experienced cytotoxic T cells (CD8 + CD45RO + Ki67 + ) and the proximity of antigen-experienced cytotoxic T cells to melanoma cells were associated with positive response to ICIs. Our study highlights the potential of multiplexed single-cell technology to quantify spatial cell-cell interactions within the tumor microenvironment to understand immune therapy responses.

22 May 2025 in Nature Cancer
Verified
Journal Article
Open access
AAAnca Apavaloaei
Anca Apavaloaei
QZQingchuan Zhao
Qingchuan Zhao
LHLeslie Hesnard
Leslie Hesnard
Maxime CahuzacMaxime Cahuzac
Maxime Cahuzac
CDChantal Durette
Chantal Durette
Claude PerreaultClaude Perreault
Claude Perreault
Melanoma and non-small cell lung cancer (NSCLC) display exceptionally high mutational burdens. Hence, immune targeting in these cancers has primarily focused on tumor antigens (TAs) predicted to derive from nonsynonymous mutations. Using comprehensive proteogenomic analyses, we identified 589 TAs in cutaneous melanoma (n = 505) and NSCLC (n = 90). Of these, only 1% were derived from mutated sequences, which was explained by a low RNA expression of most nonsynonymous mutations and their localization outside genomic regions proficient for major histocompatibility complex (MHC) class I-associated peptide generation. By contrast, 99% of TAs originated from unmutated genomic sequences specific to cancer (aberrantly expressed tumor-specific antigens (aeTSAs), n = 220), overexpressed in cancer (tumor-associated antigens (TAAs), n = 165) or specific to the cell lineage of origin (lineage-specific antigens (LSAs), n = 198). Expression of aeTSAs was epigenetically regulated, and most were encoded by noncanonical genomic sequences. aeTSAs were shared among tumor samples, were immunogenic and could contribute to the response to immune checkpoint blockade observed in previous studies, supporting their immune targeting across cancers.

22 June 2020 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
RARached Alkallas
Rached Alkallas
MLMathieu Lajoie
Mathieu Lajoie
DMDan Moldoveanu
Dan Moldoveanu
KHKaren Vo Hoang
Karen Vo Hoang
PLPhilippe Lefrançois
Philippe Lefrançois
IWIan R. Watson
Ian R. Watson

27 March 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MLMathieu Lajoie
Mathieu Lajoie
SDSimon Drouin
Simon Drouin
MCMaxime Caron
Maxime Caron
PSPascal St-Onge
Pascal St-Onge
MOManon Ouimet
Manon Ouimet
DSDaniel Sinnett
Daniel Sinnett
Pre-B cell childhood acute lymphoblastic leukemia (pre-B cALL) is a heterogeneous disease involving many subtypes typically stratified using a combination of cytogenetic and molecular-based assays. These methods, although widely used, rely on the presence of known chromosomal translocations, which is a limiting factor. There is therefore a need for robust, sensitive, and specific molecular biomarkers unaffected by such limitations that would allow better risk stratification and consequently better clinical outcome. In this study we performed a transcriptome analysis of 56 pre-B cALL patients to identify expression signatures in different subtypes. In both protein-coding and long non-coding RNAs (lncRNA), we identified subtype-specific gene signatures distinguishing pre-B cALL subtypes, particularly in t(12;21) and hyperdiploid cases. The genes up-regulated in pre-B cALL subtypes were enriched in bivalent chromatin marks in their promoters. LncRNAs is a new and under-studied class of transcripts. The subtype-specific nature of lncRNAs suggests they may be suitable clinical biomarkers to guide risk stratification and targeted therapies in pre-B cALL patients.

13 January 2024 in Clinical & Experimental Metastasis
Verified
Journal Article
Open access
PDF file
JMJamie Magrill
Jamie Magrill
DMDan Moldoveanu
Dan Moldoveanu
JGJiayao Gu
Jiayao Gu
MLMathieu Lajoie
Mathieu Lajoie
IWIan R Watson
Ian R Watson
Melanoma is a highly immunogenic malignancy with an elevated mutational burden, diffuse lymphocytic infiltration, and one of the highest response rates to immune checkpoint inhibitors (ICIs). However, over half of all late-stage patients treated with ICIs will either not respond or develop progressive disease. Spatial imaging technologies are being increasingly used to study the melanoma tumor microenvironment (TME). The goal of such studies is to understand the complex interplay between the stroma, melanoma cells, and immune cell-types as well as their association with treatment response. Investigators seeking a better understanding of the role of cell location within the TME and the importance of spatial expression of biomarkers are increasingly turning to highly multiplexed imaging approaches to more accurately measure immune infiltration as well as to quantify receptor-ligand interactions (such as PD-1 and PD-L1) and cell-cell contacts. CyTOF-IMC (Cytometry by Time of Flight - Imaging Mass Cytometry) has enabled high-dimensional profiling of melanomas, allowing researchers to identify complex cellular subpopulations and immune cell interactions with unprecedented resolution. Other spatial imaging technologies, such as multiplexed immunofluorescence and spatial transcriptomics, have revealed distinct patterns of immune cell infiltration, highlighting the importance of spatial relationships, and their impact in modulating immunotherapy responses. Overall, spatial imaging technologies are just beginning to transform our understanding of melanoma biology, providing new avenues for biomarker discovery and therapeutic development. These technologies hold great promise for advancing personalized medicine to improve patient outcomes in melanoma and other solid malignancies.

23 March 2017 in Blood
Verified
Journal Article
Closed access
PDF file
FKFida Khater
Fida Khater
MLMathieu Lajoie
Mathieu Lajoie
SLSylvie Langlois
Sylvie Langlois
JHJasmine Healy
Jasmine Healy
SCSonia Cellot
Sonia Cellot
DSDaniel Sinnett
Daniel Sinnett